NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.95 +0.25 (+6.76 %) (As of 09/21/2018 04:00 PM ET)Previous Close$3.70Today's Range$3.67 - $3.9552-Week Range$1.55 - $5.75Volume1.52 million shsAverage Volume570,677 shsMarket Capitalization$224.22 millionP/E Ratio-3.50Dividend YieldN/ABeta2.09 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California. Receive ACRX News and Ratings via Email Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ACRX CUSIPN/A Webwww.acelrx.com Phone650-216-3500 Debt Debt-to-Equity Ratio-0.15 Current Ratio4.01 Quick Ratio3.96 Price-To-Earnings Trailing P/E Ratio-3.50 Forward P/E Ratio-4.76 P/E GrowthN/A Sales & Book Value Annual Sales$7.99 million Price / Sales29.96 Cash FlowN/A Price / CashN/A Book Value($0.73) per share Price / Book-5.41 Profitability EPS (Most Recent Fiscal Year)($1.10) Net Income$-51,500,000.00 Net Margins-1,329.13% Return on EquityN/A Return on Assets-62.39% Miscellaneous Employees41 Outstanding Shares60,600,000Market Cap$224.22 million AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions What is AcelRx Pharmaceuticals' stock symbol? AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX." How were AcelRx Pharmaceuticals' earnings last quarter? AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced its earnings results on Thursday, August, 2nd. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.01. The specialty pharmaceutical company earned $0.82 million during the quarter, compared to analyst estimates of $0.93 million. View AcelRx Pharmaceuticals' Earnings History. When is AcelRx Pharmaceuticals' next earnings date? AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for AcelRx Pharmaceuticals. What price target have analysts set for ACRX? 8 analysts have issued 1 year target prices for AcelRx Pharmaceuticals' stock. Their predictions range from $2.00 to $8.00. On average, they expect AcelRx Pharmaceuticals' share price to reach $5.50 in the next year. This suggests a possible upside of 40.3% from the stock's current price. View Analyst Price Targets for AcelRx Pharmaceuticals. What is the consensus analysts' recommendation for AcelRx Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AcelRx Pharmaceuticals. What are Wall Street analysts saying about AcelRx Pharmaceuticals stock? Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock: 1. Cantor Fitzgerald analysts commented, "Zalviso offer advantages to the patient, physician/nurse and the treatment facility, that if approved and priced accordingly, we believe will drive uptake of both products beyond the Street’s current estimates which should drive the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $6." (9/20/2018) 2. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (8/14/2018) Are investors shorting AcelRx Pharmaceuticals? AcelRx Pharmaceuticals saw a drop in short interest during the month of August. As of August 15th, there was short interest totalling 3,205,974 shares, a drop of 28.5% from the July 31st total of 4,483,807 shares. Based on an average trading volume of 565,334 shares, the short-interest ratio is presently 5.7 days. Approximately 6.1% of the shares of the company are short sold. View AcelRx Pharmaceuticals' Current Options Chain. Who are some of AcelRx Pharmaceuticals' key competitors? Some companies that are related to AcelRx Pharmaceuticals include Revance Therapeutics (RVNC), Assembly Biosciences (ASMB), Cara Therapeutics (CARA), Amphastar Pharmaceuticals (AMPH), CytomX Therapeutics (CTMX), Radius Health (RDUS), Amarin (AMRN), Inflarx (IFRX), Homology Medicines (FIXX), Crinetics Pharmaceuticals (CRNX), ProQR Therapeutics (PRQR), Dynavax Technologies (DVAX), NuCana (NCNA), Flexion Therapeutics (FLXN) and TG Therapeutics (TGTX). Who are AcelRx Pharmaceuticals' key executives? AcelRx Pharmaceuticals' management team includes the folowing people: Mr. Vincent J. Angotti, CEO & Director (Age 50)Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 55)Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 49)Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 66)Mr. Anil N. Dasu, Chief Engineering Officer (Age 55) Has AcelRx Pharmaceuticals been receiving favorable news coverage? Media stories about ACRX stock have been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AcelRx Pharmaceuticals earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for AcelRx Pharmaceuticals. Who are AcelRx Pharmaceuticals' major shareholders? AcelRx Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.11%), Renaissance Technologies LLC (0.82%), FMR LLC (0.49%), Northern Trust Corp (0.12%), Granite Investment Partners LLC (0.10%) and Lincoln Capital Corp (0.07%). Company insiders that own AcelRx Pharmaceuticals stock include Lawrence G Hamel, Life Sciences Maste Perceptive, Mark G Edwards, Pamela P Palmer, Perceptive Advisors Llc, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals. Which institutional investors are selling AcelRx Pharmaceuticals stock? ACRX stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp. View Insider Buying and Selling for AcelRx Pharmaceuticals. Which institutional investors are buying AcelRx Pharmaceuticals stock? ACRX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Granite Investment Partners LLC, Lincoln Capital Corp and BlackRock Inc.. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals. How do I buy shares of AcelRx Pharmaceuticals? Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AcelRx Pharmaceuticals' stock price today? One share of ACRX stock can currently be purchased for approximately $3.92. How big of a company is AcelRx Pharmaceuticals? AcelRx Pharmaceuticals has a market capitalization of $224.22 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe. How can I contact AcelRx Pharmaceuticals? AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected] MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 330 (Vote Outperform)Underperform Votes: 273 (Vote Underperform)Total Votes: 603MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/21/2018 by MarketBeat.com StaffFeatured Article: Should You Consider an Index Fund?